2024-05-03 08:50:32
Korea United Pharmaceutical and UN S Bio announced on the 3rd that they signed a joint research agreement with Chonbuk National University Hospital’s Biomedical Research Institute and Chonbuk National University’s Airway Targeted Therapy Development Research Center to develop integrated airway targeted therapy technology.
This agreement focuses on increasing the possibility of developing innovative new drugs in the field of respiratory disease drugs and advancing the research and development infrastructure by combining professional technologies and networks in various fields of industry, academia, and disease.
Chonbuk National University Hospital and Airway Targeted Therapy Research Institute are working to develop treatments for intractable respiratory diseases based on precision medicine. They plan to develop the already secured candidate substances into an inhaled formulation of a highly efficient airway-targeted treatment using an inhaler.
The inhaler utilizes the inhalation device platform that Korea United Pharmaceutical developed for the first time in Korea and is currently pursuing commercialization. Korea United Pharmaceutical developed an inhalation device, ultra-precision powder filling machine, and unmanned automatic assembly system using pure domestic technology, and the inhalation treatment production plant completed in Sejong City has already received KGMP certification.
Unlike oral or injectable drugs, respiratory treatments using inhalers can improve treatment effectiveness and reduce side effects by delivering the drug directly to the lungs. Therefore, it is expected that drug products optimized for the treatment of respiratory diseases can be developed.
Accordingly, Chonbuk National University Hospital and Chonbuk National University Airway Targeted Therapy Research Institute plan to develop various inhalation-type treatments by combining the candidate substances being developed for the treatment of intractable respiratory diseases with Korea United Pharmaceutical’s inhalation device platform.
In addition, UNS-Bio announced that it will propose improvements through product use suitability analysis and clinical research together with Chonbuk National University Hospital and the Airway Targeted Therapy Research Institute and carry out joint research projects at home and abroad.
This agreement ceremony was attended by Kang Won-ho, CEO of Korea United Pharmaceutical and UN S-Bio, Director Myeong-Hwan Go of Chonbuk National University’s Biomedical Research Institute, and Director Lee Yong-cheol of Chonbuk National University’s Airway Targeted Therapeutics Research Institute. They pledged to work to develop innovative treatments.
Kang Won-ho, CEO of United Pharmaceutical Korea, said, “We are delighted to collaborate with Chonbuk National University Hospital’s Biomedical Research Institute and the Airway Targeted Therapy Research Institute. We will develop various respiratory disease drugs by applying our drug delivery system platform technology.”
Kim Sang-jun, Donga.com reporter ksj@donga.com
-
- great
- 0dog
-
- I’m so sad
- 0dog
-
- I’m angry
- 0dog
-
- I recommend it
- dog
Hot news now
2024-05-03 08:50:32